Engineering interferons for cancer immunotherapy.
Explore this paper's citation graph
Summary
How the development in cytokine engineering has allowed for efficient delivery of type I and type III IFNs to tumor sites is highlighted and the obstacles that are still associated with IFN-based therapies before they can be fully and safely integrated into clinical settings are looked ahead to.
- Type
- review
- Published
- 2024-09-06
- Cited by
- 4
- References
- 79
- Access
- Open access
- OpenAlex
- https://openalex.org/W4402339148
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:272462668
Keywords
Immunotherapy, Cytokine, Biology, Interferon, Immune system
References
- Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma
- Type I interferons in anticancer immunity
- Pegylation: a novel process for modifying pharmacokinetics.
- Adenovirus delivery provides extended interferon-α exposure and augments treatment of metastatic carcinoma
- Interferon-α in acute myeloid leukemia: an old drug revisited
- Antitumor activity of type III interferon alone or in combination with type I interferon against human non‐small cell lung cancer
- Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.
- Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications.
- The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression
- Anchoring interferon alpha to apolipoprotein A‐I reduces hematological toxicity while enhancing immunostimulatory properties
- Effect of pegylation on pharmaceuticals
- Interferons at age 50: past, current and future impact on biomedicine
- Therapeutic Effect of Human iPS-Cell–Derived Myeloid Cells Expressing IFN-β against Peritoneally Disseminated Cancer in Xenograft Models
- Novel Controlled-Release Lemna-Derived IFN-α2b (Locteron): Pharmacokinetics, Pharmacodynamics, and Tolerability in a Phase I Clinical Trial
- Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha.
- Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: a need for more translational study.
- High efficiency cell-specific targeting of cytokine activity
- Anti-CD20-interferon-β fusion protein therapy of murine B cell lymphomas
- Type I interferons in infectious disease
- The Fusion Protein of IFN-α and Apolipoprotein A-I Crosses the Blood–Brain Barrier by a Saturable Transport Mechanism
Cited by
Related papers
- Aspects of the innate and adaptive immune responses to acute infections with BVDV.
- Do adaptive immune cells suppress or activate innate immunity?
- Earthworm and innate immunity
- Control of adaptive immunity by the innate immune system
- Roles of Toll‐like receptors in innate immune responses
- Roles of Toll-like receptors in innate immune responses